Arthritis and Lupus Drugs Pulled Off by Pharma Companies


Arthritis and Lupus Drugs Pulled Off by Pharma Companies

Following many deaths, rheumatoid arthritis and lupus drugs are being pulled off by Swiss pharmaceutical companies Roche and Biogen. After being observed by monitoring board, the two drugs were found to be immensely infectious and even deadly in some cases.

Ocrelizumab is still reportedly being tested for people who suffer from relapsing remitting multiple sclerosis. The expected sale of 800 million francs is therefore being denied by Roche. Zurich exchange reported a dip of 0.6% at 179.60 Swiss francs in sales of Roche.

Roche had said that before the drug was proved to be causing some serious infections, earlier last year, at the last stage of its trail, was confirmed that it had a powerful impact on curbing the effect of rheumatoid arthritis.

Roche cited a review which said, "The safety risk outweighs the benefits observed in these specific patient populations at this time after detecting serious and opportunistic infections, some of which were fatal".

National Rheumatoid Arthritis Society states that Rheumatoid arthritis is detected in 20 million people and results in stiff, swollen and painful joints after inflation caused by deficiency of immunity.

Latest News

Deutsche Bank Q3 Loss may be a Record One in a Decade
Volkswagen Scandal Worries the City of Wolfsburg
Strong Component Sale and Weak Won help Samsung’s Third Quarter Profits
Is the U.S. Shale Oil Boom Heading Towards the Beginning of Its End?
Volkswagen Plans to Launch a Recall in January and Fix the Affected Diesel Cars
BOJ Keep Record Stimulus Unchanged
BP Plc will Pay $20 Billion as Penalties for the Deadly Oil Spill of 2010
Ben Bernanke says Larger Number of Executives Involved in 2008 Financial Crisis
United’s New CEO Oscar Muñoz Aims at Improving relation with Workers
The September Job Number Hint at a Sluggish Patch
First Data Launches its IPO, Targets to Raise Up to $3.7 Billion
ConAgra’s Head Quarter Move Announcement gets Positive but ‘Muted’